ArticleThe Journal of biological chemistry2026
Reciprocal compensation of caspase-2 and p53 regulates the DNA damage response in HCT116 colon cancer cells.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Caspase-2 has positive and negative effects on tumor growth in different cancer models. The mechanisms determining these dual outcomes of caspase-2 activation are unclear underscoring the need to assess caspase-2 function in different cell types. We report that high caspase-2 expression is associated with lower survival in patients with colon cancer and increased tumor size in HCT116 colon cancer xenografts. We investigated the interplay between caspase-2 and p53 in regulating the proliferation of these cells. While neither of these proteins had much of an effect on cell cycle arrest on their own, deficiency in both caspase-2 and p53 led to slower proliferation, prolonged G1 cell cycle arrest, and impaired homologous recombination. Caspase-2 loss resulted in increased p53 transcription and activation, while p53 loss resulted in increased caspase-2 activation suggesting that these two proteins compensate for each other. Strikingly, loss of caspase-2 led to disruption of p53-dependent transcription and enhanced the ability of p53 to bind to the promoter regions of the genes encoding mouse and human double minute 2 and p21. These results were unique to the HCT116 cells, but activation of the WNT pathway in RKO, a second colon cancer cell line, caused them to phenocopy HCT116 cells with respect to the requirement for caspase-2 and p53 for the DNA damage response. Our data support a model in which caspase-2 and p53 can compensate for the loss of each other to ensure cell cycle and homologous recombination proceed correctly. Together, our data suggest that inhibiting both proteins would be detrimental to colon cancer cell growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.